Monica M. Bertagnolli, MD, Elected ASCO President for 2018-2019 Term

Five New Members Elected to ASCO Board of Directors and Nominating Committee
For immediate release
December 15, 2016


Gaye Walker

ALEXANDRIA, Va. -- Monica M. Bertagnolli, MD, a long-time member and volunteer, has been elected to serve as the President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to the ASCO Board of Directors, as well as two new members to the ASCO Nominating Committee.

“Serving as ASCO President is a tremendous personal honor for anyone in the field of oncology,” said Dr. Bertagnolli. “Much more importantly, it is an opportunity for me to make a meaningful difference by providing a strong voice in the health care community for those whom I consider to be my particular constituency: clinical and translational researchers, community and academic oncologists participating in clinical research and surgical oncologists.”

An active ASCO member since 1995, Dr. Bertagnolli is chief of the division of Surgical Oncology at Dana-Farber/Brigham and Women’s Cancer Center, a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Bertagnolli has served on the ASCO Board of Directors, the Cancer Prevention Committee, and the Strategic Planning Committee, among others.

Dr. Bertagnolli will be the first ASCO President-Elect to serve 4 years on the ASCO Board (first year as President-Elect, second year as President and Chair of the Board, third year as Chair of the Board, and fourth year as Past President), following the Bylaws changes that were approved by members in May 2016.

Newly Elected ASCO Board Members

ASCO's Board of Directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field. The following physicians will begin four-year terms as members of ASCO's Board of Directors starting in June 2017:

Reshma Jagsi, MD, DPhil, has been elected to an Undesignated Specialty seat. She is professor and deputy chair of the Department of Radiation Oncology at the University of Michigan, where she is residency program director, treats patients with breast cancer, and conducts health services research. An ASCO member since 2004, Dr. Jagsi has served on the CancerLinQ™ Data Governance Oversight Committee, the Bisphosphonates in Breast Cancer and Breast Cancer Consensus Panels, the Scientific Program Committee and the Journal of Clinical Oncology Editorial Board. She is also a past chair of the Ethics Committee. Dr. Jagsi is a past participant in ASCO’s Leadership Development Program and has served as an ASCO representative to the American Medical Association.

Michael P. Kosty, MD, FACP, FASCO, has been elected to a Community Oncologist seat. Dr. Kosty is a member of the Scripps Clinic Medical Group, where he has practiced hematology and medical oncology since 1989, and is currently the director of Scripps Green Cancer Center and the director of Graduate Medical Education and the Hematology/Oncology Fellow Training Program at Scripps Clinic/Scripps Green Hospital. Since joining ASCO in 1986, Dr. Kosty has served as the chair of the Cancer Education Committee Continuing Medical Education Subcommittee, the Workforce Advisory Group, and the Professional Development Committee Oncology Training Program Subcommittee, as well as a member of the Scientific Program Committee and Bylaws Committee, among others. He is currently chair-elect of the Professional Development Committee and a member of the Leadership Development Working Group, and was recently the ASCO Lead for the NCI-ASCO Teams in Cancer Care project. In recognition of his years of service to the Society, Dr. Kosty received the distinction of Fellow of ASCO (FASCO) in 2014.

Eric J. Small, MD, FASCO, has been elected to a Medical Oncologist seat. Dr. Small is the deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco, and professor in residence in the Department of Medicine and Department of Urology. He has held several volunteer and leadership positions since he joined ASCO in 1992, including associate editor of the Journal of Clinical Oncology; chair of the Molecular Markers Scientific Committee, the Scientific Program Committee, and the inaugural Prostate Cancer Symposium Steering and Program Committees; and a member of the ASCO Nominating Committee and the Conquer Cancer Foundation Grants Selection Committee. Dr. Small was named a Fellow of ASCO (FASCO) in 2015.

Newly Elected Members of ASCO Nominating Committee

The following physicians will each serve a three-year term on the ASCO Nominating Committee:

Cora N. Sternberg, MD, FACP, will serve as Chair of the Nominating Committee in 2019-2020. Dr. Sternberg is the chief of the department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, adjunct professor at La Sapienza University in Rome, adjunct professor of Urology and Urological Oncology at Tufts University Medical School, and adjunct professor at Temple University’s College of Science and Technology. Since joining ASCO in 1985, Dr. Sternberg has served ASCO in a variety of capacities. She was the scientific chair of the Prostate Cancer Symposium Program Committee, ASCO’s representative to the Prostate Cancer Symposium Steering Committee, a member of the Genitourinary Symposium Program Committee, and a member of the International Affairs Committee Advisory Group. Dr. Sternberg was the Genitourinary Cancer Track Leader of the Scientific Program Committee for the 2014 ASCO Annual Meeting and has also served on the Editorial Board of the Journal of Clinical Oncology.

Debra A. Patt, MD, MPH, MBA, is the vice president of Public Policy and Academic Affairs at Texas Oncology and a medical oncologist at Texas Oncology Cancer Center. Dr. Patt also serves as the medical director of the Pathways Task Force at McKesson Specialty Health/The US Oncology Network, the medical director of Publications and Outcomes at McKesson Specialty Health, the medical director of the Breast Cancer Committee at Seton Family of Hospitals, and the leader of breast health services for The University of Texas Dell Medical School at Austin. Dr. Patt joined ASCO in 2005 and is currently the Breast Cancer Track leader for the Cancer Education Committee, chair of the Clinical Practice Committee, and editor-in-chief of JCO Clinical Cancer Informatics and ASCO’s Clinical Cancer Advances report. Dr. Patt is a past participant in ASCO’s Leadership Development Program and was awarded a Conquer Cancer Foundation of ASCO Young Investigator Award in 2006.



About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.